Dear Colleague,
We are delighted that you have confirmed your consent and agreed to resubscribe to PCSK9 Forum to receive important information and updates from us.
Kind regards,
John Chapman and Henry Ginsberg
News
Two more analyses show efficacy of alirocumab in diabetesOSLER: sustained benefit with evolocumab in statin intolerant patientsTwo more analyses show efficacy of alirocumab in diabetesOSLER: sustained benefit with evolocumab in statin intolerant patientsThe lipoprotein(a) – LDL cholesterol conundrumLipoprotein(a) – does it matter when LDL cholesterol is low?EVACS: Impact of evolocumab on LDL, plaque and inflammation in ACSADA 2018: BANTING trial shows that evolocumab further reduces LDL-C and non-HDL-C in type 2 diabetes patients
